USFDA18 May 2026, 11:34 am
Piramal Pharma's Digwal facility receives Establishment Inspection Report
AI Summary
Piramal Pharma Ltd. announced that the US FDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Digwal, Telangana, India. This signifies the successful closure of the US FDA inspection at the facility. The company is submitting this information following the receipt of the EIR.
Key Highlights
- US FDA issues Establishment Inspection Report (EIR) for Piramal Pharma's Digwal facility.
- The US FDA inspection at the Digwal manufacturing facility has been successfully closed.
- Piramal Pharma discloses the receipt of the EIR to the stock exchange.